Form 10 Explorer
10-K
Annual Report
ADIAL PHARMACEUTICALS, INC.

ADIL

NASDAQ

CIK: 1513525

File #: 001-38323

Period End: Dec 31, 2023

Fiscal Year: 2023

View on EDGAR
Balance Sheet
36 line items · 2 periods
XBRL
ItemDec 31, 2023Dec 31, 2022
Current Assets:
Cash and cash equivalents
2,827,0824,001,794
Prepaid expenses and other current assets
371,597349,441
Current assets of discontinued operations
428,700
Total Current Assets
3,198,6794,779,935
Discontinued Operations
428,700
Intangible assets, net
3,9134,477
Equity method investment
1,534,013
Equity Method Investments
1,534,013
Assets of discontinued operations
948,392
Total Assets
4,736,6055,732,804
Discontinued Operations
1,377,092
Current Liabilities:
Accounts payable
103,325276,410
Discontinued Operations
117,424
Accounts payable, related party
24,062
Accrued expenses
477,747963,327
Discontinued Operations
191,490
Accrued expenses, related party
47,942175,000
Other current liabilities
10,387
Current liabilities of discontinued operations
365,742
Total Current Liabilities
653,0761,790,866
Discontinued Operations
365,742
Long-term Liabilities:
Long-term liabilities of discontinued operations
665,444
Total Liabilities
653,0762,456,310
Discontinued Operations
1,031,186
Stockholders’ Equity
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 1,663,421 and 1,067,491 shares issued and outstanding at December 31, 2023 and 2022, respectively
1,6631,067
Additional paid in capital
72,879,73866,949,958
Accumulated deficit
(68,797,872)(63,674,531)
Total Stockholders’ Equity
4,083,5293,276,494
Common Stock
1,6631,067
Additional Paid In Capital
72,879,73866,949,958
Accumulated Deficit
(68,797,872)(63,674,531)
Total Liabilities and Stockholders’ Equity
4,736,6055,732,804